益生菌联合柳氮磺胺吡啶治疗炎症性肠病  

Effect of combine probiotics with SASP on inflammatory bowel disease

作　　者：金志元[1] 

机构地区：[1]浙江省湖州市第一人民医院,浙江湖州313000

出　　处：《现代中西医结合杂志》2008年第3期333-334,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的评价益生菌联合柳氮磺胺吡啶对炎症性肠病的疗效。方法以本院92例住院和门诊的轻中度炎症性肠病患者为研究对象,随机分成2组,一组为益生菌联合柳氮磺胺吡啶治疗组,另一组为单用柳氮磺胺吡啶对照组。治疗8周后观察2组患者的主观评价、总体评价以及内镜复查的情况。结果治疗组患者的主观评价明显高于对照组(P<0.05),临床缓解率也高于对照组(P<0.05)。而内镜复查结果2组无显著性差异(P>0.05)。结论益生菌对炎症性肠病的治疗是有效的和安全的。Objective It is to evaluate the therapeutic effect of probiotics and SASP in patients with inflammatory bowel disease（IBD）.Methods This is a randomized clinical trial for 8 weeks.92 patients with mild-moderate IBD were divided into 2 groups,one treatment group was treated by probiotics and SASP,and another control group was treated by SASP only.The patients′ feeling,total estimation and condition of endoscopy were evaluated after the treatment.Results It was obviously well on patients′ feeling in treatment group than in control group（P〈0.05）,and was also obviously well on clinical remission rate（P〈0.05）,but there was no difference on condition of endoscopy（P〉0.05）.Conclusion Probiotics can improve the clinical efficacy of inflammatory bowel disease,and was safe.

关 键 词：益生菌 炎症性肠病 柳氮磺胺吡啶 

分 类 号：R516.1[医药卫生—内科学]